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A B S T R A C TQuality-adjusted life-years (QALYs) are widely used as an outcome
for the economic evaluation of health interventions. However,
preference-based measures used to obtain health-related utility
values to produce QALY estimates are not always included in key
clinical studies. Furthermore, organizations responsible for reviewing
or producing health technology assessments (HTAs) may have pre-
ferred instruments for obtaining utility estimates for QALY calcula-
tions. Where data using a preference-based measure or the preferred
instrument have not been collected, it may be possible to ‘‘map’’ or
‘‘crosswalk’’ from other measures of health outcomes. The aims of
this study were 1) to provide an overview of how mapping is currently
used as reported in the published literature and in an HTA policy-
making context, specifically at the National Institute for Health and
Clinical Excellence in the United Kingdom, and 2) to comment on best
current practice on the use of mapping for HTA more generally. The
review of the National Institute for Health and Clinical Excellencesee front matter Copyright & 2013, International
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.1016/j.jval.2012.10.010
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ndence to: Louise Longworth, Health Economics Resguidance found that mapping has been used since first established
but that reporting of the models used to map has been poor.
Recommendations for mapping in HTA include an explicit considera-
tion of the generalizability of the mapping function to the target
sample, reporting of standard econometric and statistical tests
including the degree of error in the mapping model across subsets
of the range of utility values, and validation of the model(s). Mapping
can provide a route for linking outcomes data collected in a trial or
observational study to the specific preferred instrument for obtaining
utility values. In most cases, however, it is still advantageous to
directly collect data by using the preferred utility-based instrument
and mapping should usually be viewed as a ‘‘second-best’’ solution.
Keywords: health-related quality of life, methodology, quality-adjusted
life-years, utility assessment.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The use of ‘‘mapping’’ techniques or ‘‘crosswalks’’ to link the out-
comes from different measures of health or health-related quality of
life (HRQOL) have become increasingly popular within health eco-
nomics, particularly for the purpose of conducting cost-utility
analyses of health technologies or other health interventions [1].
These methods have been particularly useful when the studies used
to estimate the effectiveness of the interventions have not collected
health-related utility data. In addition, where a health technology
assessment (HTA) or reimbursement agency has recommended the
use of a specific preference-based measure, the mapping approach
can be used to link to health-related utility values for that instru-
ment by using outcomes obtained from other measures.
This is the situation in the United Kingdom, where the
National Institute for Health and Clinical Excellence (NICE) has
stated that its economic evaluations should be presented by
using an incremental cost per quality-adjusted life-year (QALY)
framework [2]. It has also indicated that preferably the estimates
of health-related utility used in QALY calculations should have
been obtained by using the EuroQol five-dimension (EQ-5D)
questionnaire. This recommendation has arisen from the evi-
dence that estimates of health state utility differ according to theinstrument and/or elicitation method used. Therefore, in the
context of NICE, there is a need to map to, or predict, EQ-5D data,
even where other measures of health-related utility have been
collected.
There are various options available to the analyst when
considering the use of mapping for the estimation of health state
utilities for HTA. What measures to map to and which measures
to map from? What form should the model underpinning the
algorithm take? Which statistical methods should be used? How
should results be tested, validated, and reported? This is evident
from the considerable variation in the approaches reported in the
growing body of literature on mapping studies for cost-utility
analyses. There are also currently no clear guidelines on the best
methods and standards available. Throughout the article, map-
ping to the EQ-5D is provided as an example; however, the issues
and methods discussed can equally apply to other instruments
for measuring health-related utility. The references to the EQ-5D
reflect that this instrument is the most commonly mapped to
within this area [1] and also reflects that the study was originally
conceived to support NICE and its stakeholders when using
mapping techniques [3].
The aims of this article were threefold: 1) to provide
an overview of how mapping is currently used in an HTASociety for Pharmacoeconomics and Outcomes Research (ISPOR).
earch Group, Brunel University, Uxbridge, Middlesex UB8 3PH, UK.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 2 0 2 – 2 1 0 203policy-making context, specifically at NICE in the United King-
dom; 2) to provide an overview of the broader literature on
mapping; and 3) to provide guidance on best practices where
this is possible based on the findings of the two reviews.Methods
What Is Meant by ‘‘Mapping’’?
In mathematical terms, ‘‘mapping’’ refers to correspondence by
which each element of a given set has associated with it one or
more elements of a second set [4]. In the context presented here,
we define ‘‘mapping’’ as the development and use of a model or
algorithm to predict health-related utility values by using data
from other measures of health outcomes. While the term ‘‘map-
ping’’ is used in many other health-related contexts, we are
primarily interested in its use to obtain EQ-5D values. The focus
is on empirical mapping as this is consistent with NICE recom-
mendations [2]. Other forms of mapping based on parametric
approaches or qualitative analyses are not considered further.
Furthermore, we distinguish ‘‘mapping’’ studies from studies
directly eliciting health-related utility values by asking partici-
pants to directly value their own health state, and from studies in
which a description of a hypothetical health state generated from
a vignette or other instrument is valued. In the context of NICE in
the United Kingdom, this latter approach of valuing health states
described by other instruments (specifically validated patient-
reported outcome measures) is recognized as a possibility when
the EQ-5D has been demonstrated to be inappropriate for the
particular condition of interest [5].
In this context of mapping, the data used to predict EQ-5D
values could consist of condition-specific quality-of-life mea-
sures (such as the asthma quality-of-life questionnaire [6]), other
generic quality-of-life questionnaires (such as the short form 36
health survey (SF-36) [7]), clinical indicators of disease severity
(such as the Canadian Cardiovascular Society Score for angina [8]
or the Psoriasis Area and Severity Index [9]), sociodemographic
variables, or a combination of these. Data on the ‘‘target’’
preference-based measure (in this case, the EQ-5D) and the
‘‘source’’ predictive measure(s) (the measures of health outcomes
that will be used to map to the preference-based measure) must
be collected within a separate estimation sample. From these
sample data, models can be developed to estimate the relation-
ship between the target measure and other measures of health
outcomes. Where the target measure is a multiattribute instru-
ment, the data can be mapped to either the EQ-5D utility value or
the EQ-5D dimension responses. A set of predicted EQ-5D values
can then be obtained by applying the statistical model to data
contained in the study of effectiveness. The predicted EQ-5D values
can then be analyzed using standard methods for trial-based
analyses or summarized for each health state within an economic
model. For example, to map SF-36 to the EQ-5D, an estimation
sample is used to estimate models regressing the EQ-5D on SF-36
variables. The model is used as a prediction equation to predict the
EQ-5D in the clinical trial or other study of interest that contains SF-
36 data, and these predicted values can then be used in an
economic model. Alternatively, if a published function mapping
SF-36 to the EQ-5D exists, this may be used rather than estimating
the mapping function by using an estimation sample.
In its simplest form, mapping can be considered equivalent
to taking the mean value for a given health state. For
example, consider the case of a condition categorized into two
health states: stable disease and progressive disease. If EQ-5D
data and the health state category were collected for a sample of
patients, we could estimate the mean utility value for patients at
each of the two stages of disease. These mean values could thenbe assigned to patients in a trial in which the stage of disease is
recorded. However, simply using a mean value (and distribution
where reported) for a similar broadly defined health state from
another data set or the reported literature can mask the variation
between patients.
Whether the mapping approach will offer an advantage over
simply using mean values from an external data set will, in part,
depend on the structure of the economic model being used to
reflect the decision problem. If the model has a simple structure
with few health states, then reliable estimates of the mean (and
variance) of the EQ-5D values associated with those health states
may suffice. Where there are multiple predictors of health status
that can be measured and reflected in the decision model,
however, then the mapping approach can predict the EQ-5D
value more accurately. For example, if the health states in a
model are defined according to a 20-point measure of disease
severity, it may not be possible to obtain values for each of these
20 levels of severity from a sufficient number of patients.
However—providing there is a predictable relationship between
the EQ-5D and the severity measure—the relationship between
the measures can be estimated on the basis of all the data to
provide estimates for each of the 20 health states. Mapping also
enables the EQ-5D data to be linked directly back to data collected
within the clinical trial(s) used to inform the estimates of cost-
effectiveness.
Overview of Mapping from the Health Economics Literature
An overview of the methods used for mapping to estimate
health-related utility values is provided. It draws on a previously
conducted review of published studies reporting empirical results
of mapping exercises [1]. The overview considers the following
elements of mapping in turn:1. Defining the ‘‘estimation’’ data set
2. Model specification
3. Model type
4. Assessing performance
5. ApplicationEach of these stages will be discussed in turn below with
reference to the published literature on mapping. Although
specific reference is given to the EQ-5D, the approaches described
below could apply to other preference-based measures of HRQOL.
Identification of best practice is stated where possible.
Review of the Use of Mapping at NICE
The use of mapping in a policy-making context will be presented
with specific reference to NICE in the United Kingdom. The 2008
NICE Guide to the Methods of Technology Appraisal recommends
that HRQL data be collected directly from patients by using the
EQ-5D and that consideration be given to ‘‘mapping’’ or ‘‘cross-
walking’’ from other HRQOL measures to the EQ-5D when such
data are not available [2]. Although the 2008 edition was the first
of the NICE methods guides to suggest mapping as a potential
solution for an absence of health-related utility data, previous
methods guides recommend self-assessment of health status by
patients [10] and data from validated generic preference-based
measures [11] but did not offer guidance to the analyst on how to
conduct cost-utility analyses if such data had not been collected
within clinical studies.
Two published reviews of NICE Technology Appraisals are
available that report on the methods used to obtain the health-
related utility values included in its HTAs [12,13]. These reviews
report the methods of eliciting the values (e.g., time trade-off and
standard gamble), the instruments used to collect information
on changing health status (e.g., the EQ-5D questionnaire), and
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review articles were examined for reference to mapping and the
results considered in relation to NICE’s stated guidance on the
use of mapping. In addition, the more recent review was updated
to include evidence submissions since the publication of the
updated 2008 NICE Methods Guide. All technology appraisals
published since the previous review and up to July 2010 were
reviewed to identify appraisals where mapping had been used to
obtain health-related utility data. The same data extraction
methods and template as used in the published review were
used to extract and analyze the data from these appraisals [13].Results
An Overview of Mapping
Mapping involves three key stages. First, a separate ‘‘estimation’’
data set is required that contains the data that you are mapping
from, the ‘‘source,’’ and the ‘‘target’’ preference-based measure.
Second, regression methods are used to ‘‘map’’ this data onto
either the index score or the classification system of the target
measure. Third, the regression results are applied to the trial(s) or
observational study data set to estimate preference-based scores
for the target measure at either the mean or observational level.
Ideally, a validation stage should also be applied, whereby the
regression results are validated against another data set.
The Estimation Sample
The generation of the mapping function involves the estimation
of the statistical relationship between the target measure and the
predictive measure(s) by using an estimation data set. The first
step in the mapping approach is to obtain the estimation sample.
As this assumes that the statistical relationship is the same
across the estimation and trial data sets, the choice of the
‘‘estimation sample’’ is crucially important.
The estimation sample is the group of people, usually
patients, who will complete the preferred instrument (in this
example, the EQ-5D) to report their own health and from whom
data on the ‘‘source’’ measures will also be obtained. To be
confident about the generalizability of the mapping function to
the target sample, the clinical and demographic characteristics of
people in the estimation sample should be as similar as possible
to the characteristics of the sample to which the mapping
algorithm will be applied. All covariates used in the mapping
function should be overlapping in distribution for the estimation
and target samples. It is recommended that all variables included
within the target source (e.g., the main clinical trial(s) used to
inform clinical effectiveness within the economic model) that are
thought likely to have an impact on target EQ-5D values should
be included in the estimation sample. If no existing data set is
available that includes both the source and the target measure, it
will be necessary to collect the data to estimate the mapping
regression. One study that uses this approach followed the same
inclusion and exclusion criteria for recruiting the estimation
sample as the clinical trial that was the target for the mapping
[14]. It may also be possible to use an estimation sample
including a wider range of observations, provided that the full
range of clinical and demographic characteristics is captured
within the estimation sample (see, e.g., [15,16]). However, the
ability of the mapping algorithm to predict EQ-5D values of the
target population will depend on its relevance to that population.
For example, there are several articles mapping the cancer-
specific European Organization for the Research and Treatment
of Cancer (EORTC) quality of life questionnaire core-30 (QLQ C30)
onto the EQ-5D for different cancer patient groups. The mappingregressions differ between the different patient samples used to
estimate the mapping algorithm, and one possible explanation is
that the algorithms may not be generalizable to different cancer
conditions [17–20]. This is an area that requires further research.
Alternatively, ‘‘double mapping’’ has been used in unpub-
lished studies, where it has not been possible to obtain a data
set that contains both the source and target measures. This
involves one estimation data set to map from the source to an
intermediary measure and a second estimation data set to map
from the intermediary measure onto the target measure. These
estimates should be treated with caution as the process gener-
ates intermediary measure estimates that are then used to
generate estimates, meaning that mapping twice is likely to
increase the error and uncertainty around the predicted EQ-5D
questionnaire estimates. If this approach is taken, the uncer-
tainty should be fully accounted for within the economic
analysis.
Model Specification
The model specification can take a number of forms depending
on which best suits the data and the decision problem at hand. If
the target preference-based measure is a multiattribute utility
measure (i.e., has multiple dimensions such as the EQ-5D), the
dependent variable could either be the utility index value or the
responses to the dimensions of health described by the instru-
ment. The explanatory variables should be those that best predict
the preference-based values for health states included in the
economic analysis. If the mapping function is intended to have
wider use by other researchers, consideration will need to be
given to whether the explanatory variables are routinely collected
in other studies. The model form will depend on the data:
additive models are currently most commonly used; however,
alternative model specifications have been used in the literature.
A recent review of mapping studies included a systematic
search of the literature supplemented by unpublished studies
(identified by contacting researchers) in early 2007 and reports on
30 studies covering 119 mapping models [1]. The review of the
literature found that the most common target measure was
the EQ-5D (15 studies). The most commonly used source mea-
sures in the literature were SF-36 (7 studies) and short-form 12
(SF-12) (6 studies). The most common model specification
involved the use of a preference-based index (usually for the
EQ-5D) as the dependent variable and dimension or item scores
(usually from the SF instruments) as independent variables.
Articles also examined model specifications including squared
terms and interaction terms to explore possible nonlinear rela-
tionships between the target and source measures. The review
found that these had little impact, but it is likely that this differs
by source and target measures, patient group, and patient severity.
The review found that the inclusion of nonhealth variables such as
sociodemographics made some improvement in the accuracy of
the mapping function. Table 1 provides a summary of different
model specifications for the mapping function.
The recent review of mapping studies found that explanatory
power using R2 was often low for models that involved mapping a
condition-specific measure onto a generic preference-based mea-
sure and errors were often larger than for models mapping a
generic measure onto a generic preference-based measure [1].
This may occur because of limited conceptual overlap as impor-
tant dimensions in the condition-specific measure may not
appear in the generic measure and vice versa.
The estimation of the mapping regression relies on statistical
dependence between the target measure (e.g., the EQ-5D) and the
source measures, and the avoidance of omitted variables. If the
source measures have little conceptual overlap with the dimen-
sions of the EQ-5D, the regression model may suffer from omitted
Table 1 – Overview of mapping process and recommendations.
Estimation sample Clinical and demographic characteristics in the estimation sample should be similar to the characteristics of
the ‘‘target’’ sample to which the mapping algorithm will be applied
Covariates used in the mapping function should be overlapping in distribution for the estimation and target
samples
Variables included within the target sample thought likely to have an impact on EQ-5D values should be
included in the estimation sample
If no data set is available that includes the explanatory variables and the EQ-5D data, data collection of EQ-5D
data will be required to estimate the mapping regression
Dependent variables EQ-5D index
EQ-5D dimension levels
Independent variables Condition-specific measure: overall score, summary scores, item-level scores, item-level dummies, interaction
terms, squared terms, cubic terms
Generic measures: overall score, summary scores, item-level scores, item-level dummies, interaction terms,
squared terms, cubic terms
Clinical measures: overall score, summary score, categorical dummies
Sociodemographic variables
Other relevant health data
Model selection and
specification
Use prior knowledge of clinical relationships
Use standard statistical techniques to examine the data prior to mapping estimation (e.g., frequency tables and
correlations)
Fully describe the data set used to estimate the regression model including both range of EQ-5D and plots
showing EQ-5D distribution
Fully describe the range of EQ-5D predicted values used in the cost-effectiveness model
Model type Linear ordinary least squares
Tobit
Censored least absolute deviation
Two-part model
Generalized linear model
Latent class mixture model
Censored mixture model
Multinomial logit model
Performance Goodness of fit: Statistical significance, sign and size of coefficients R2 and adjusted R2
Information criterion of AIC and BIC
Further tests of model fit such as Ramsey RESET test, Park test, Jarque-Bera test Plots to examine whether
model assumptions are valid
Predictive ability: Root mean squared error (RMSE) and mean squared error (MSE)
RMSE, MSE, mean error, mean absolute error by subset of severity range of the EQ-5D and/or predictive
measure(s) Plots of observed and predicted EQ-5D scores
Validation Application and assessment of mapping algorithm when applied to a validation sample
Validation sample can be a separate patient sample to the estimation data set or the data set used to estimate
the mapping function can be randomly separated into estimation and validation samples
Uncertainty Uncertainty in health-related utility values should be incorporated into economic analyses
Multiple possible mapping functions can be used to produce utility values for sensitivity analyses
AIC, Akaike’s information criterion; BIC, Bayesian information criterion; EQ-5D, EuroQol five-dimensional.
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tion errors. This can undermine the model, and the uncertainty
around the predicted values may be substantial. Where the EQ-
5D is shown to not adequately capture the impact of the
condition or treatment, it may be necessary to consider using
an alternative approach to utility estimation.
The selection of explanatory variables should be based on a
combination of judgment based on prior knowledge of the clinical
relationships between variables, and standard statistical and
econometric techniques. Consideration should be given to the
variables that are expected to have an impact on the EQ-5D values
of people with the condition of interest. This can be based on
patient and clinical opinion obtained directly or reported in the
literature. Decision rules for the inclusion of variables could be
specified a priori, such as levels of statistical significance and thesigns of the coefficients matching prior stated beliefs. Correlation
should be used to examine the relationship between source and
target measures, and if there is poor correlation, this indicates that
the mapping function will perform poorly (see [21] for an example
of this). Akaike’s information criterion ([22]) and the Bayesian
information criterion ([23]) can be used to inform the choice of
model specification (see, e.g., [24].) Other tests should also be used
to enable the researcher to define a robust model, such as
examining the extent to which the model suffers from misspeci-
fication (e.g., Ramsey RESET test [25]), omitted variables and
heteroscedasticity (e.g., the Park test [26]), or nonnormality in
the errors (e.g., the Jarque-Bera test [27]; see Brazier et al. [28] for
an explanation of its usage in panel data).
The severity of the condition reflected in the source measure
should also be captured by the target measure. If the source
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levels of severity or impairment described by the target measure
(e.g., the EQ-5D), it will not be able to accurately predict these levels.
The extent to which this is a problem will depend on the severity
range of the target and source measures and the severity range of
the estimation and trial data set. The data set used to estimate the
mapping regression should be fully described including both the
range of predicted EQ-5D values and graphical plots showing the
distribution of the predicted EQ-5D data. The range of predicted EQ-
5D values used in the cost-effectiveness model should also be fully
described to provide information of whether the predicted EQ-5D
data have involved extrapolation.
Model Type
The appropriate model type differs depending on the data set and
how it is applied. For multiattribute systems such as the EQ-5D, it also
depends on whether the aim is to predict the index value or whether
it is to predict responses to each of the dimensions of health
described by the instrument. As specified earlier, the properties of
the regression data set should be clearly outlined. These properties
should then be used to inform model selection and a justification
provided explaining why the selected regression model was chosen.
This is further discussed below with particular reference to the
commonly used EQ-5D.
Mapping to EQ-5D Index Values
The model type used to map source measures onto the EQ-5D
should take into account the distribution of EQ-5D values in the
estimation data set. The EQ-5D has been shown to exhibit ceiling
effects, meaning that typically EQ-5D data sets have a substantial
proportion of people reporting full health with an EQ-5D value at
1. Although the distribution of EQ-5D utility values varies by
patient group and study, often a bimodal or trimodal distribution
is observed, with one peak around full health, one peak for
moderate states, and a further peak for more severe states. The
recent mapping review [1] found that the most common estima-
tion technique was ordinary least squares (OLS), yet linear
regressions may not always accurately predict the EQ-5D dis-
tribution for high and low EQ-5D values [1,16].
Some of the standard model specifications have been shown
to predict fewer values toward the extremes of the utility scale,
even where they are evident in the observed source data. OLS has
been criticized in particular as being inappropriate for regres-
sions mapping onto the EQ-5D due to the bounded nature of EQ-
5D values as by definition people cannot have an EQ-5D value
higher than 1, which represents ‘‘full health.’’ In addition, the
standard UK value set has a lowest possible value of 0.594. The
OLS model does not restrict the range of values and therefore
may lead to implausible predicted values outside the existing
range of EQ-5D values. Researchers have explored alternative
types of models to overcome the theoretical limitations of OLS
models for the analysis of EQ-5D values, including tobit [16,29,30]
and censored least absolute deviation (CLAD) [16,29–31]. The
results of this research have been mixed, with some concluding
that CLAD provides an improvement in model performance
compared with OLS [16,29,30], others stating that the improve-
ment of CLAD over OLS is small [18], and the review of mapping
studies finding that the use of tobit and CLAD had little impact.
Most of the models are based on mean values, apart from CLAD,
which is a median model. The choice between the use of mean
and median values requires normative judgments as well as
statistical considerations. Health valuation for economic evalua-
tion for decision making has been mainly based on mean models
to date; however, there has been some recent research utilizing
median models [20,32–34].The choice and application of alternative models is an area of
recent and ongoing research, and a large number of models have
been recently explored in the mapping literature. This includes
the use of models to address the EQ-5D distribution including a
generalized linear model (GLM) [35], a latent class model [31], a
two-part and two step model (TP/TS) or two-step model
[31,35,36], and a random effects censored mixture model [24].
The first part of the TP/TS model uses a logit regression to
estimate the probability that an individual (at the observational
level) is in full health and the second part estimates EQ-5D
utilities for individuals who are not in full health using OLS
[31,35,36], a GLM [35], or a log-transformed EQ-5D index (TP/TS-L
model) [31] (although note that these articles combine the two
models differently to produce predicted utilities). One article
addresses overprediction for severe health states by estimating
separate regressions for mild and severe states and using cutoff
points on the source measure to identify which model should be
used to predict EQ-5D values at the observational level [37].
The results from this recent research have been mixed. The
studies estimating these models found that TP/TS models and
GLMs do not seem to offer an improvement on OLS in terms of
performance. The possibility of negative utility values must be
considered when using a TP/TS model or a GLM. The study using
the TP/TS-L model reported that all values in its data set were
positive [31]. The study including the GLM used gamma and log-
normal distributions (where the dependent variable was expressed
as a disutility) and found that the models using the gamma
distribution did not converge [35]. This study also found that OLS
had superior performance to both the GLM and the TP/TS model
[35]. Another study found that OLS regression was more accurate
than the CLAD model, the multinomial logit model, and the TP/TS
model at estimating the group mean, yet the accuracy deteriorated
in older and less healthy subgroups and for these the TP/TS model
performed better [36]. The latent class model can handle data
where there are more than two ‘‘classes’’ in the data, and so it is
more flexible to deal with the trimodal distribution of the EQ-5D at
estimating the group mean values. One study [31] found that the
latent class model and the TP/TS-L model performed better than
OLS, CLAD, and a TP/TS model using OLS in the second stage. An
adjusted censored mixture model has been used to deal with the
bimodal or trimodal distribution of EQ-5D values, and although
high errors were observed, the authors concluded that the method
offers a vast improvement in performance in comparison to OLS
and tobit based on other selection criteria [24]. Further research
using the latent class model, the TP/TS-L model, and random
effects censored mixture model is encouraged, especially for
smaller patient data sets as existing research has been conducted
on relatively large data sets, which may not be typical for the data
sets used to estimate mapping functions for NICE submissions
[31,24].
Mapping to the EQ-5D Dimension Responses
Although EQ-5D utility value sets are usually treated as contin-
uous, in practice they take a limited number of discrete values.
An alternative approach is to map to the descriptive system
of the measure, which enables the value set to be applied
separately and therefore may better reflect the distribution of
values that would have been obtained if collected directly. This
approach has several benefits. It can facilitate the use of the
mapping function in different countries or jurisdictions as value
sets from other countries can be applied to predictions from the
mapping exercise. This can reduce the burden on companies
required to produce HTAs for multiple reimbursement agencies in
different countries as mapping to EQ-5D utility values would
require the estimation of separate mapping functions for each
country-specific value set. In addition, it is likely to reduce the
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mapping functions for each specific country or jurisdiction. The
most commonly used approach to mapping to the EQ-5D dimen-
sions has been through the use of logistic regression. Some
articles reported using a multinomial logit model to estimate
separate mapping functions to predict the level of each dimension
of the EQ-5D, and then applying the standard published value sets
to obtain utilities [36,38]. Articles comparing this approach to
other approaches, however, found that it did not offer an
improvement [16,36].
Assessing Performance
Measures of explanatory power such as R2 report how well the
mapping function explains the variation in utilities in the
estimation data set. Although this is a useful indicator of
performance, it does not show whether the mapping function
is equally appropriate across the entire range of utilities that can
be produced by the target measure. If the aim of mapping is to
estimate EQ-5D data when such data are unavailable from the
primary source of effectiveness, the accuracy of predictions is a
key aspect of performance. Mean absolute error (mean absolute
difference between estimated and observed utilities) and root
mean squared error both indicate the ‘‘error’’ in the estimates in
the data set used to estimate the regression, and smaller errors
are preferred. While these errors are not necessarily representa-
tive of the errors in the estimates when the results are applied in
the separate data set, they can provide some indication of how
large the errors are expected to be.
Some mapping studies have reported underprediction for EQ-
5D values representing mild health states and overprediction for
more severe states (see, e.g., [16,24,39]), with better prediction for
mild and moderate states. In the literature, however, surprisingly
few studies report error across subset range, meaning that
the true extent of the problem cannot be determined. Errors
should be reported across subsets of the EQ-5D range (e.g., EQ-
5Do 0, 0r EQ-5Do 0.25, 0.25r EQ-5D o 0.5, 0.5r EQ-5Do 0.75,
0.75r EQ-5Dr 1), and a plot of observed and predicted values
should be used. These are useful for indicating whether there is
systematic bias in the predictions and whether heteroskedasti-
city is present. If there is systematic bias in the predictions,
consideration will need to be given to how it impacts on the
results of the cost-effectiveness analysis: for example, if the bias
could systematically favor one intervention over another. In
addition, errors reported across subsets of the range of the
predictive measure(s) (see [24], e.g.) can inform application of
the mapping algorithm in the trial data set and reporting this
should be considered.
Some studies divide their estimation data set into two
samples: an estimation sample and a validation sample (e.g.,
[39–42]). The mapping function is estimated on the estimation
sample, and its performance is examined by using the validation
sample. This has the advantage that it assesses the mapping
function by its prime purpose; however, it reduces the sample
size of the estimation sample. A randomly allocated split of the
data should enable the analyst to assess how well the algorithm
predicts the EQ-5D values for the validation sample. If predictive
ability is poor when assessed on the basis of a nonrandom split of
the data, it may not be possible for the analyst to judge whether
the poor performance is due to the functional form of the model
or a lack of generalizability to a systematically different popula-
tion. The reduced precision in the coefficients of the mapping
function from the reduction in sample size may be overcome by
reestimating the mapping model by using the full data set once
the specification of the model has been assessed by using the
split-sample approach. If the division of the estimation data set
into two is truly random, the model is expected to perform well;however, this does not necessarily indicate that it will perform
similarly when applied to the trial data if the characteristics of
the sample are different from those of the estimation and
validation samples.
Application—Reflecting Measurement Error and
Heterogeneity
There are at least three sources of measurement error when
using mapping to estimate the EQ-5D or other health-related
utility data from preference-based measures. These include
heterogeneity in the measurement of the utility index values
(e.g., as reflected in the standard errors from the general popula-
tion valuation surveys of the preference-based measure). In
addition, it includes the measurement error arising from the
source and target measures (e.g., the self-reported description of
own health on the EQ-5D, and the measurement error associated
with other measures of health outcomes used to link the source
and target measures). In addition, there is also the error arising
from the estimation of the relationship between the source and
target measures. While all possible sources of measurement error
are not always fully reflected when presented, it is important to
bear in mind that mapping can contribute to this latter further
source of error as a result of the mapped values being predicted
rather than directly reported. Furthermore, some researchers
have shown that the confidence intervals around the predicted
values as a result of mapping tend to be narrower than the
confidence intervals around directly observed values, reflecting a
reduction in the heterogeneity of the utility values [40,41].
As a minimum, the parameter uncertainty in the estimated
regression analysis should be taken into account by using the
variance-covariance matrices in the probabilistic sensitivity
analysis (see [43] for an overview). If there are multiple possible
mapping functions, these can be applied in sensitivity analyses
to give an indication of the uncertainty associated with the
choice of the algorithm. Alternative algorithms, however, captur-
ing plausible forms of the relationship between the predicted EQ-
5D values and alternative explanatory variables may not be
available. Further research is needed to establish the best ways
of capturing all the uncertainty in the mapped EQ-5D values.
Until then analysts and decision makers should be aware that
uncertainty and heterogeneity around mean mapped values may
be underestimated.
Application—Use of Previously Developed Mapping Functions
Generating a de novo mapping function gives the analyst control
over the inclusion and exclusion criteria for the estimation
sample, and therefore influence over the generalizability of the
mapping function to the target population. However, existing
mapping functions may be available in the literature to the
analyst. In these circumstances, we recommend that careful
consideration be given to the generalizability of the mapping
function to the target population, including the range of disease
severity over which the function was estimated and the potential
for systematic differences in the populations that could have an
impact on the EQ-5D values. Most of the considerations outlined
above would also apply to the review and use of published
algorithms. There may be circumstances in which all the variables
included in the published algorithm are not available to the
analyst in the data set. Applying these algorithms is still theore-
tically possible by applying mean values to these variables; how-
ever, this reduces the granularity in the resulting estimates.
The Use of Mapping in NICE Technology Appraisals
Mapping has been most commonly used in NICE submissions where
health-related utility data have not been directly collected within the
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techniques, however, have also been used to incorporate health-
related utility data collected directly within the main clinical trial of
interest into economic models, where the structure of the model is
driven by other outcome measures. For example, an economic model
may have been constructed to define health states by using a clinical
measure of disease severity. In this case, mapping techniques can be
used to explain the relationship between the two measures and to
estimate the utility value (or distribution of values) associated with a
health state defined by the clinical measure. An alternative approach
would be to simply estimate the mean and variance for each of the
health states described by the model from the data collected. For
example, in the case of treatment for rheumatoid arthritis, the
Health Assessment Questionnaire [44] is a commonly used measure
of clinical outcomes. Several studies have sought to explain the
relationship between health-related utility and Health Assessment
Questionnaire scores by using mapping-type methods (see [24] for a
recent overview). It is possible to use this approach even when utility
data have been collected directly within the primary source(s) for
clinical effectiveness, as a means of incorporating the data within
the economic model. Care should be taken, however, so that the
estimated mapping function accurately reflects the observed data
from the trial when applied to the model.
The NICE Methods guidance refers to predicting EQ-5D data as
the target variable but is not restrictive about the source measures
from which the EQ-5D data are predicted. Reference is given to
measures included in the clinical trials [2]; however, this is not
restrictive and other types of studies may be more appropriate in
some circumstances; for example, if the events of interest are
rarely observed within a trial setting.
Other explicit recommendations made by NICE include that
the mapping should be based on empirical data. This means that
both the EQ-5D and the measure(s) used to map from are
administered in a sample of people to generate empirical data,
rather than researchers attempting to map on the basis of
judgment (or other expert opinion) alone or the face value of
the measures. Also, the adequacy of the mapping function should
be demonstrated and validated, and the statistical properties of
the function should be described [2]. The guidance is not pre-
scriptive in stating which statistical or other tests should be
undertaken; however, the most appropriate statistical and econo-
metric tests have been discussed above.
Of the two reviews of the health-related utility data, the early
review focused on independent assessment reports produced for the
Technology Appraisals Programme up to May 2003 [12]. The authors
report two clear cases of mapping in appraisals using empirical
data: one where data from the Health Assessment Questionnaire
were mapped onto the EQ-5D and another where data from the
Child Health Assessment Questionnaire were mapped onto the EQ-
5D. The methods used to undertake the mapping were reported to
be limited or not reported at all. Stein et al. [12] identified a further
five appraisals where health states had been mapped to preference-
based instruments by using opinion rather than empirical data. In
two cases, the mapping was conducted on the basis of clinical
opinion, in one case it was based on opinions of the HTA analysts,
and no details were provided in the remaining two cases. All but one
of the HTAs mapped health states onto the EQ-5D; the other HTA
mapped health states onto the Index of Health-Related Quality of Life.
The second published review of health-related utility data
included in NICE included 46 appraisals conducted from the time
of the implementation of the 2004 Methods Guide up to the time
that the current Methods Guide was introduced in 2008 [13]. It
included the independent assessment reports and the evidence
dossiers submitted by the sponsors of technologies. Thirty-nine
appraisals included cost-utility analyses; when including both
independent and sponsor submissions, this accounted for 71
individual cost-utility analyses submitted to NICE. The reviewfound that the use of mapping had increased since the previous
review to over a quarter of submissions over the period of the
review (n ¼ 19). Empirical data were used to generate the
mapping mechanism in 16 submissions, 1 was based on expert
opinion, and the methods used in the other 2 submissions were
unclear. Six of the submissions used published mapping algo-
rithms in their analyses, and a further appraisal used an existing,
but unpublished, algorithm. The majority of submissions
included analyses that mapped onto the EQ-5D (n ¼ 14). Other
end points for the mapping process included the health utilities
index (n ¼ 2), short-form 6 dimension (derived from SF-36) (n ¼
1), and patients’ time trade-off values for their own health (n ¼ 2).
In most cases, health-related utility data were mapped from
condition-specific measures (n ¼ 14); the remainder mapped
from generic HRQOL measures (n ¼ 2) or nonstandardized
vignettes of health states (n ¼ 1), or the details were unclear
(n ¼ 2).
The updated review found that although the 2008 Guide
explicitly allowed mapped estimates of health-related utility to
be included in submissions, its use had actually fallen. Of the 44
appraisals, only 4 included mapping to estimate health-related
utility data. All four appraisals based the mapping algorithm on
empirical data. They were based on previously developed map-
ping algorithms that were publicly available as fully published
studies (n ¼ 2), in abstract form (n ¼ 1), or from a previous NICE
HTA report (n ¼ 1). All four HTAs mapped from a condition-
specific measure of either HRQOL or disease severity. Half of
these analyses mapped data onto EQ-5D values, and the other
half mapped onto patients’ time trade-off values of their own
health. The submissions contained little information about the
statistical properties of the mapping algorithms; however, they
did provide references to the original documents that described
how the algorithms were developed.
The evidence from NICE Technology Appraisal submissions to
date suggests that although mapping has been used in submis-
sions from the very early beginnings of NICE, the level of detail
with which the mapping algorithms and analyses have been
presented in the documentation has been generally poor, with
few details of the statistical performance of the mapping algo-
rithms being presented to the NICE Technology Appraisal Com-
mittee. In addition, much of the source data has included clinical
measures of health or condition-specific measures of HRQOL.
This is in contrast to the majority of the published literature
identified that maps from other generic measures of HRQOL
(such as the SF-36) to the EQ-5D.Conclusions
The main advantage of mapping in this context is that it can
facilitate the estimation of health-related utility for cost-utility
analysis where the utility data have not been directly collected,
either at all or using the preferred utility instrument. It is
particularly useful for organizations such as NICE that need a
consistent approach to measuring and valuing health outcomes.
In most cases, however, it will still be preferable to collect utility
data directly rather than to introduce additional uncertainty into
the estimates as a result of having to estimate the utility values
on the basis of responses to other measures of health outcomes.
This enables the data collected to directly reflect the impact of
treatment on overall HRQOL, rather than just on the variables
used to estimate the mapping algorithm. For example, if the
mapping algorithm includes only a clinical measure, the map-
ping function may not reflect the impact of other effects of
treatment that are not captured by the clinical measure. In
addition, uncertainty and errors around the estimates can affect
the accuracy of the EQ-5D utilities when used in economic
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data sources are most appropriate, for example, where the trials
are small or do not capture significant numbers of events that are
expected to have an impact on HRQOL.
Much of the interest in mapping to date has focused on the
EQ-5D as the target measure for mapping algorithms. Mapping to
the EQ-5D should be used only when the EQ-5D is appropriate for
that patient group and condition. All generic measures and the
EQ-5D in particular may not be appropriate for all patient groups
and conditions, and alternative methods such as the use of
condition-specific preference-based measures may be considered
to be more appropriate under these circumstances.
The review of NICE guidance has shown that there has been a
decline in the practice of using researcher or clinical opinion to
map between measures; however, the reporting of mapping
studies is still poor in NICE submissions. Most of the mapping
studies that have been included in NICE submissions have
mapped from condition-specific measures of quality of life or
clinical indicators of disease severity. The literature search for
the recent mapping review [1] demonstrated that there was little
published evidence examining the suitability of mapping in
patient data sets. Since that review was conducted, however,
mapping studies estimated by using patient data sets have been
increasingly used and published.
We undertook an updated literature search by using the same
search strategy as the recent review and found 31 studies
meeting the inclusion criteria after an initial title sift. The large
number of studies that were identified signals the recent popu-
larity of mapping, and many of these articles offer methodologi-
cal developments to approaches undertaken prior to 2007. The
development and use of mapping algorithms for use in HTA is a
developing area of methodological and applied research. Recent
developments include approaches such as mapping between
preference-based measures using general population visual ana-
logue scale values for both measures valued alongside each other
[46]. Recent developments in associated areas that may be
informative for the mapping literature include mapping between
Rasch scores and utility scores [47], the use of Gaussian processes
[48], and single equation and two-part beta regression models
estimated by using maximum-likelihood, quasi-likelihood, and
Bayesian Markov-chain Monte Carlo methods [49].
One study suggests that the performance of different models
varies at the overall and subgroup levels [36], two studies found
no significant difference between mapped and observed QALY
estimates [19,45], yet one of these studies found that incremental
cost per QALY estimates differed across four interventions using
observed and mapped EQ-5D scores [45]. Further research is
needed examining the performance of mapping functions and
estimation techniques across subgroups of patients. Further
research needs to compare and develop different models, develop
methods for incorporating error and uncertainty into the mapped
estimates, and assess the impact of using mapped estimates
rather than observed EQ-5D values in economic evaluation.
Recommendations for good practice based on current evi-
dence are summarized in Table 1. This includes basing mapping
on direct statistical association rather than purely on the opinion
of one more ‘‘expert.’’ The characteristics of the estimation
sample should be similar to, and overlapping in, distribution
with the target sample for the mapping analysis, although in
some circumstances, it may be appropriate for the estimation
sample to include a broader range of people, provided that the
target sample is sufficiently represented. Standard statistical
techniques can be used to examine the data prior to mapping
estimation to inform model selection and specification.
Improvements in the reporting of mapping are needed includ-
ing reporting of the estimation data sets, econometric models,
and predicted estimates. The range of observed utility valuesfrom the estimation sample and predicted utility values used in
the cost-effectiveness model should be described and the use of
visual plots can be helpful. Reporting errors across subsets of the
utility range can be particularly helpful for identifying systematic
differences in performance across disease severities. The most
appropriate model will differ depending on the data set and how
it is applied. Wherever possible, the model should be validated.
Ideally, this would be conducted by using an external sample
similar to the target sample. It is unlikely, however, that this will
be available in many cases. Where the sample size is large
enough to do so, it is recommended that the sample be randomly
split to provide an estimation subsample and a validation
sample. The final model specification can then be reestimated
by using the full sample.
In most cases, mapping should be considered at best a
second-best solution to directly collected utility data. If there is
no overlap in content between the measures of interest, mapping
is unlikely to be able to appropriately capture the relationship to
estimate health-related utility. Alternative methods for estimat-
ing health-related utility data should be considered in these
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